Scynexis (SCYX) Cash & Equivalents (2013 - 2026)
Scynexis (SCYX) posted Cash & Equivalents of $36.7 million for Q1 2026, up 72.5% on a QoQ basis from $21.3 million in Q4 2025, and down 31.84% year-over-year from $53.8 million in Q1 2025.
Scynexis (SCYX) Cash & Equivalents (2013 - 2026) Analysis & Trends
Scynexis' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $36.7 million for Q1 2026.
- Quarterly Cash & Equivalents fell 31.84% year-over-year to $36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (down 31.84% YoY) and the FY2025 annual result came in at $21.3 million, up 32.45% from the prior year.
- Cash & Equivalents was $36.7 million for Q1 2026 at Scynexis, up from $21.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $118.7 million in Q2 2022 and bottomed at $11.0 million in Q2 2025.
- A 5-year average of $51.6 million and a median of $37.9 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 53.31% — and 2025, when it sank 86.83%.
- Scynexis' Cash & Equivalents stood at $45.8 million in 2022, then dropped by 25.68% to $34.0 million in 2023, then sank by 52.86% to $16.1 million in 2024, then surged by 32.45% to $21.3 million in 2025, then jumped by 72.5% to $36.7 million in 2026.
- Business Quant data shows SCYX's Cash & Equivalents at $36.7 million in Q1 2026, $21.3 million in Q4 2025, and $37.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | 36.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.67 Mn |
| Dec 31, 2025 | 21.26 Mn |
| Sep 30, 2025 | 37.90 Mn |
| Jun 30, 2025 | 11.02 Mn |
| Mar 31, 2025 | 53.80 Mn |
| Dec 31, 2024 | 16.05 Mn |
| Sep 30, 2024 | 28.73 Mn |
| Jun 30, 2024 | 83.70 Mn |
| Mar 31, 2024 | 35.48 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Sep 30, 2023 | 105.20 Mn |
| Jun 30, 2023 | 57.91 Mn |
| Mar 31, 2023 | 26.91 Mn |
| Dec 31, 2022 | 45.81 Mn |
| Sep 30, 2022 | 68.62 Mn |
| Jun 30, 2022 | 118.70 Mn |
| Mar 31, 2022 | 95.21 Mn |
| Dec 31, 2021 | 104.48 Mn |
| Sep 30, 2021 | 100.11 Mn |
| Jun 30, 2021 | 112.40 Mn |